Metabolic syndrome and idiopathic sudden sensori-neural hearing loss

Massimo Rinaldi, Giada Cavallaro, Marica Cariello, Natasha Scialpi, Nicola Quaranta

1 Otolaryngology Unit, Department of Biomedical Sciences, Neuroscience and Sensory Organs, University of Bari “Aldo Moro”, Bari, Italy, 2 Clinica Medica Cesare Frugoni, Department of Interdisciplinary Medicine, University of Bari Aldo Moro “Aldo Moro”, Bari, Italy

* nicolaantonioadolfo.quaranta@uniba.it

Abstract

The purpose of this study was to evaluate the association between the presence of Metabolic Syndrome (MetS) and idiopathic sudden sensorineural hearing loss (ISSHL) and the impact of MetS on recovery of patients with ISSHL. 39 Patients with ISSHL and 44 controls were enrolled in this study. Demographic, clinical characteristics and hearing recovery were evaluated. MetS was defined according to the diagnostic criteria of International Diabetes Federation (IDF) consensus definition. Patients affected by ISSHL presented a body mass index (BMI), waist circumference, waist hip ratio (WHR), fasting glucose and blood pressure significantly higher compared to controls. Considering patients with central obesity, 5 controls and 15 ISSHL patients met the criteria of MetS. According to Siegel criteria, a complete or partial recovery was observed in 60% of patients with MetS and in 91.66% of patients without MetS. MetS was associated with ISSHL and this association negatively influenced the hearing recovery of these patients.

Introduction

Idiopathic sudden sensorineural hearing loss (ISSHL) is defined, according to American Academy of Otolaryngology, as a hearing loss of at least 30 dB over 3 contiguous test frequencies occurring within a 72-h period [1]. The incidence of ISSHL is approximately 10/100,000 person per year, with no differences in gender and affected side [2]. Pathogenesis of ISSHL is controversial. Viral infections, vascular occlusions, immune-mediated mechanisms and cochlear membrane breaks have been proposed as pathogenic mechanisms, however clinical and experimental evidence that confirm one or other mechanisms is lacking [3]. Recently, in patients affected by ISSHL, endothelial dysfunction [4,5] and a high prevalence of cardiovascular risk factors [6] have been reported. Prospective studies have shown that patients affected by ISSHL have a higher risk of developing a cerebrovascular accident especially if ISSHL is associated with vertigo [7,8], suggesting that hearing loss may share similar etio-pathogenic mechanisms.

Metabolic syndrome (MetS) is a complex disorder defined by a cluster of interconnected factors that increase the risk of cardiovascular atherosclerotic diseases and diabetes mellitus type 2 [9,10]. The International Diabetes Federation has proposed the diagnostic criteria of...
MetS, that is defined by the presence of central obesity (which is measured by waist circumference with gender and ethnicity specific values) and any two of the following: raised triglycerides (> 150 mg/dL (1.7 mmol/L), or specific treatment for this lipid abnormality), reduced HDL cholesterol (< 40 mg/dL (1.03 mmol/L) in males, < 50 mg/dL (1.29 mmol/L) in females, or specific treatment for this lipid abnormality), raised blood pressure (BP) (systolic BP > 130 or diastolic BP > 85 mm Hg, or treatment of previously diagnosed hypertension), raised fasting plasma glucose (FPG) (> 100 mg/dL (5.6 mmol/L), or previously diagnosed type 2 diabetes) [11]. Chien et al [12] in a case control study have reported that MetS increase the risk of sudden hearing loss and that the risk increase with the number of MetS components. In addition the presence of MetS has been associated with poorer hearing recovery by other authors [13–15] that however have not used central obesity as a criterion for MetS.

The aim of the present study was therefore to evaluate the association between the presence of MetS and ISSHL and the influence of MetS on the prognosis of ISSHL.

Material and methods

Study population

39 Patients with ISSHL and 44 age and sex matched control were enrolled in this study from January 2017 to November 2018. All patients denied previous episodes of ISSHL and none started the treatment before undergoing hearing and blood tests. Exclusion criteria were hearing loss caused by acoustic neuroma, central lesions, autoimmune disorders, Meniere’s disease, multiple sclerosis, trauma, medication, noise, or prior ear surgery. All ISSHL patients were treated with the standard medical protocol, which included steroids (prednisone 1 mg/kg die with tapering), carbogen (95% CO2 and 5% O2) inhalation, pentoxifylline, vitamin C, magnesium sulfate.

Anthropometric and clinical parameters

The demographic, anamnestic and clinical characteristics are shown in Table 1. Height (cm), weight (kg), waist and hip circumference and blood pressure were measured, and body mass index (BMI) (kg/m2) was calculated. A fasting blood sample was obtained for measuring plasma glucose, total cholesterol (TC), high (HDL-C) and low (LDL-C) density lipoprotein cholesterol and triglycerides (TG). For MetS we used diagnostic criteria based on IDF consensus definition, in addition each participant was considered a “current daily smoker” if they regularly smoked at least 5 cigarettes/day during the previous 3 months or had stopped smoking less than 1 year before admittance to our department [16].

Audiovestibular investigation

All of the patients underwent a standard evaluation that consist of bed side examination, pure tone audiometry, speech audiometry, tympanometry with stapedial reflexes; auditory brainstem responses (ABR), Vestibular Evoked Myogenic Potential (VEMPS) and Magnetic Resonance Imaging (MRI) of the internal auditory canal with gadolinium. The air conduction pure-tone average (PTA) was obtained by averaging the air conduction thresholds at 0.25, 0.5, 1, 2, 3, 4 and 8 kHz. Pure-tone and speech audiometry were tested at hospitalization, at hospital discharge and 1 month after discharge. Hearing Recovery was evaluated with the Siegel’s criteria [17]. Complete recovery was considered when final hearing level was better than 25dB. Patients who showed >15 dB hearing gain and whose final hearing level was between 25 and 45 dB were defined as “partial recovery”. “Slight recovery” meant a final hearing level over 45 dB with hearing gain >15 dB. Patients who showed <15 dB gain was considered “no

Competing interests: The authors have declared that no competing interests exist.
improvement”. In the present study as in Zhang et al [13], complete and partial recovery were defined as “recovered” and slight and no recovery were defined as “no recovered”.

The study was performed in accordance with the principles of the 1983 Declaration of Helsinki. The study has been executed according to the normal clinical practice guidelines and the analysis was ex-post on data that do not interfere with patients’ privacy. All the data were entered in a computerized database and were anonymized and de-identified prior to analysis. The study protocol was approved by the Ethical Committee of the Azienda Ospedaliero-Universitaria Policlinico di Bari, Italy. All patients gave their informed consent for the use of clinical data. Statistical analysis was performed using the Software R 3.5.2.

Student t-test were performed to assess comparisons among two groups in terms of continuous variables. Pearson $\chi^2$ test was used for comparisons in terms of categorial variables. P<0.05 was considered statistically significant.

Results
Characterization of the study population

The study group comprised 39 patients affected by ISSHL (23 males and 16 females) and 44 controls. Table 1 reports the demographic and clinical characteristics of the patients.

| Table 1. Characterization of the study population. |
|-----------------------------------|------------------|------------------|--------|
| CONTROL | ISSHL | p value |
| Age (year) | 48.34 ± 11.13 | 53.70 ± 13.73 | 0.0531 |
| Male | 24 (55.55%) | 23 (58.97%) | 0.7548 |
| Female | 20 (45.45%) | 16 (41.03%) | 0.1892 |
| Smokers | 17 (38.64%) | 11 (18.21%) | 0.3188 |
| BMI (Kg/m2) | 25.23 ± 3.52 | 26.80 ± 3.44 | 0.0436 |
| **BMI classes** | |
| Underweight/ Normal Weight (BMI <25) | 21 (47.73%) | 13 (33.33%) | 0.1857 |
| Overweight (25 ≥ BMI >30) | 18 (40.91%) | 21 (53.85%) | 0.2413 |
| Obese (BMI ≥ 30) | 5 (11.36%) | 5 (12.82%) | 0.8394 |
| Waist (cm) | 86.51 ± 6.36 | 96.95 ± 13.77 | <0.0001 |
| WHR | 0.94 ± 0.08 | 0.98 ± 0.10 | 0.0465 |
| Glycaemia (mg/dl) | 87.20 ± 11.85 | 101.30 ± 18.65 | <0.0001 |
| SBP (mmHg) | 116.25 ± 11.11 | 131 ± 14.40 | <0.0001 |
| DBP (mmHg) | 76.25 ± 7.63 | 80.1 ± 8.85 | 0.0363 |
| TC (mg/dl) | 188.89 ± 38.44 | 193.69 ± 37.27 | 0.5663 |
| HDL-c (mg/dl) | 54.61 ± 13.33 | 56.08 ± 13.19 | 0.6157 |
| LDL-c (mg/dl) | 113.87 ± 32.28 | 118 ± 33.80 | 0.5709 |
| TG (mg/dl) | 103.04 ± 69.47 | 106 ± 66.6 | 0.8439 |
| TG-HDL ratio | 2.25 ± 2.43 | 2.19 ± 2.04 | 0.9040 |
| LDL-HDL ratio | 2.20 ± 0.85 | 2.25 ± 0.89 | 0.7943 |
| TC-HDL ratio | 3.64 ± 1.21 | 3.65 ± 1.11 | 0.9689 |
| AIP | 0.23 ± 0.29 | 0.23 ± 0.31 | 1.0000 |

Data are presented as mean ± SEM (standard error of the mean). Abbreviations: Body Mass Index, BMI; Waist Hip Ratio, WHR; systolic blood pressure, SBP; diastolic blood pressure, DBP; total cholesterol, TC; triglyceride, TG; high-density lipoprotein cholesterol, HDL-c; low-density lipoprotein cholesterol, LDL-c; atherogenic index of plasma, AIP.

https://doi.org/10.1371/journal.pone.0238351.t001
Patients affected by ISSHL presented a BMI, waist circumference, WHR (waist to hip ratio), fasting glucose and blood pressure significantly higher compared to controls.

MetS distribution in study population

In 19 controls and 10 ISSHL patients, central obesity was in the normal value range, therefore, they did not present MetS. In 20 controls and 14 ISSHL is patients, central obesity represented a MetS criterion but they did not present other 2 MetS criteria, therefore also these patients did not have MetS diagnosis. The number of patients without a diagnosis of MetS was significantly higher in control group compared to ISSHL group. Considering patients with central obesity, 5 (11.36%) controls and 15 (38.46%) ISSHL patients met the criteria of MetS, the difference between the two groups was statistically significant (Table 2). In patients with central obesity we evaluated the number of MetS Criteria met and the means of MetS Criteria met, for each group. ISSHL patients presented a higher number of MetS criteria compared to controls. These data are showed in Table 3.

Audiometric parameters before, at discharge and after 30 days

In the whole group before treatment average PTA on the affected ear (PTA_Pre AE) was $61.7 \pm 27.9$ dB HL and on the opposite ear (PTA_CL) was $23.8 \pm 22.1$ dB HL. Average PTA on the affected ear at discharge (PTA_D) was $47.5 \pm 34.2$ dB HL and $43.5 \pm 33.3$ dB HL after 30 days (PTA_30D). Complete recovery at 30 days was present in 19 patients (48.72%), partial recovery in 12 (30.77%), slight recovery in 2 (5.13%) and no recovery in 6 (15.38%). ISSHL patients were divided in 2 groups according to the presence of MetS. No significant differences were found in terms of pre- and post-treatment hearing both on the affected and contralateral ear (Table 4).

### Table 2. Number of patients with and without diagnosis of MetS in control and ISSHL group.

| MetS                             | CONTROL | ISSHL | p value |
|----------------------------------|---------|-------|---------|
| NO MetS Patient without central obesity | 19 (43.18%) | 10 (25.64%) | 0.0964 |
| Patients with central obesity and with < 2 MetS Criteria met | 20 (45.45%) | 14 (35.90%) | 0.3801 |
| TOTAL NO MetS | 39 (88.63%) | 24 (61.54%) | **0.0042** |
| MetS Patients with central obesity and with >2 criteria met | 5 (11.36%) | 15 (38.46%) | 0.0042 |
| TOTAL MetS | 5 (11.36%) | 15 (38.46%) | **0.0042** |

All data are presented as number (%).

https://doi.org/10.1371/journal.pone.0238351.t002

### Table 3. Number and mean of MetS criteria met in central obesity patients for each group.

| MetS Criteria met in patients with central obesity | CONTROL | ISSHL | p value |
|---------------------------------------------------|---------|-------|---------|
| 0                                                 | 6 (24.00%) | 4 (13.79%) | 0.3400 |
| 1                                                 | 14 (56.00%) | 10 (34.48%) | 0.1159 |
| 2                                                 | 3 (12.00%) | 9 (31.04%) | 0.0964 |
| 3                                                 | 2 (8.00%) | 4 (13.79%) | 0.5036 |
| 4                                                 | 0 (0%) | 2 (6.90%) | 0.1848 |
| Mean of MetS Criteria met in patients with central obesity | 1.04 ± 0.84 | 1.66 ± 1.11 | **0.0265** |

Number of MetS criteria met are presented as Number (%). Mean of MetS criteria met are presented as mean ± SEM (standard error of the mean).

https://doi.org/10.1371/journal.pone.0238351.t003
Table 4. Audiometric parameters in ISSHL.

|                | PTA_Pre AE | PTA_CL  | PTA_D   | PTA_30D  |
|----------------|------------|---------|---------|----------|
| MetS (dB)      | 61.02 ± 28.66 | 31.42 ± 18.07 | 52.79 ± 35.83 | 50.75 ± 36.51 |
| No MetS (dB)   | 61.66 ± 24.71 | 22.03 ± 8.85  | 48.31 ± 29.41 | 45 ± 28.63  |
| P value        | 0.9435     | 0.0693  | 0.673   | 0.6078   |

Data are presented as mean ± SEM (standard error of the mean). Abbreviations: Mean of Pure Tone Average in affected ear before treatment, PTA_Pre AE; Mean of Pure Tone Average in contralateral ear, PTA_CL; Mean of Pure Tone Average at discharge, PTA_D; Mean of Pure Tone Average after 30 days, PTA_30D.

https://doi.org/10.1371/journal.pone.0238351.t004

Table 5. Recovery rate in patients with and without MetS, according to Siegel criteria.

|                  | Total (39) | MetS (15) | No MetS (24) | P value |
|------------------|------------|-----------|--------------|---------|
| Complete Recovery| 19 (48.72) | 5 (33.33) | 14 (58.33)   | 0.1336  |
| Partial Recovery | 12 (30.77) | 4 (26.67) | 8 (33.33)    | 0.6652  |
| Recovered        | 31 (79.49) | 9 (60.00) | 22 (91.66)   | 0.0187  |
| Slight Recovery  | 2 (5.13)   | 1 (6.67)  | 1 (4.17)     | 0.7340  |
| No Recovery      | 6 (15.38)  | 5 (33.33) | 1 (4.17)     | 0.0154  |
| No Recovered     | 8 (20.51)  | 6 (40.00) | 2 (8.34)     | 0.0187  |

Data are presented as Number (%). Recovered: complete and partial recovery; No Recovered: slight and no recovery. Siegel Criteria: Complete recovery: final hearing level is better than 25dB; Partial recovery: >15 dB hearing gain and final hearing level is between 25 and 45. Slight recovery: final hearing level over 45 dB with hearing gain >15 dB. No improvement: <15 dB gain.

https://doi.org/10.1371/journal.pone.0238351.t005

Recovery rate in MetS and No MetS group

Analysis of recovery rates according to Siegel criteria confirmed that MetS had a negative association with the rate of recovery from ISSHL; in fact, a complete or partial recovery was observed in 60% of patients with MetS and in 91.66% of patients without MetS (Table 5). The number of patients who showed a slight or no recovery was significantly higher in MetS group than in No MetS group (40% VS 8.34%).

Discussion

MetS and ISSHL are both considered risk factors for cerebrovascular accidents especially if the hearing loss is associated with vertigo [7–10]. In the present study we have evaluated the association between the presence of MetS and ISSHL and we have showed that the average of MetS criteria met by ISSHL patients were significantly higher compared to controls. In particular, compared to controls, ISSHL patients presented a significantly higher BMI, waist circumference, WHR (waist to hip ratio), fasting glucose and blood pressure. Similar results were reported by Chien et al in 2015 [12] that used, as in the present study, abdominal circumference as the main diagnostic criterion to define MetS.

Abdominal obesity has been shown to be independently associated with the other MetS components and represents by itself a risk factor for cardiometabolic diseases [11,18,19].

Abdominal obesity is associated with macrovascular and microvascular dysfunction, in particular preclinical and clinical studies have shown that obesity induce endothelial dysfunction that disrupts blood flow, reduces vascular tone and impairs the blood brain barrier [20]. The inner ear is a high metabolic organ without collateral blood supply, therefore an impaired cochlear blood perfusion mediated by endothelial dysfunction could induce hearing loss and
prevent the therapeutic agents reaching the impaired tissue through the blood circulation [4,21].

In the present study ISSHL patients presented higher levels of fasting glucose compared to controls and similar results were reported by other authors [22,23]. It has been proposed that hyperglycemia, together with insulin resistance and excessive fatty acid production may contribute to atherosclerosis onset and microvascular dysfunction with subsequent damage and apoptosis of endothelial cells [24,25] leading to sudden hearing loss.

As reported by Jalali and Nasimidoust Azgomi [26] also in the present study ISSHL patients presented higher blood tension values compared to controls. There is however limited evidence regarding the relation between hypertension and risk of hearing loss. While cross-sectional studies have shown higher prevalence of hearing loss among people with hypertension [27,28], a prospective study has suggested no association between hypertension and hearing loss [29].

In the present study we did not find higher levels of lipids in ISSHL patients. Similar results were reported by Chang et al [30], while other authors have reported a correlation between ISSHL and hyperlipidemia [31,32]. The role of hyperlipidemia needs therefore to be further investigated.

In the present study MetS was associated with a poorer hearing recovery. In particular although hearing level at admission was not different between the two groups, subjects without MetS presented a significantly higher rate of recovery compared to those with MetS.

The role of MetS as a negative prognostic factor in ISSHL has been reported by different authors [13–15], in addition hearing recovery has been negatively correlated with the single components of MetS such as diabetes [13,15] and hyperlipidaemia [13].

Zhou et al. [15], in a series of 228 patients affected by ISSHL, showed that MetS was associated with poorer hearing recovery; similar results were reported by Zhang et al [13] in 94 patients and Jung et al in 124 patients [14]. It should be noted that in all these studies obesity was evaluated with the BMI and not with the waist circumference.

The present study is therefore the first that correlates poor hearing recovery with abdominal obesity, that as previously stated, is associated with insulin resistance and endothelial dysfunction mediated by inflammation and reactive oxygen species [9].

MetS could induce therefore a subclinical damage at the level of the cochlea that not only favours the loss of hearing in case of external stressors, but also reduce the cochlear “reserve” influencing hearing recovery.

Other authors have evaluated the prognostic role of other cardiovascular risk factors in ISSHL prognosis. Hyperglycaemia has been reported as a negative prognostic factor for recovery in ISSHL [22,33], and microvascular dysfunction and hyperglycemia induced neuropathy have been proposed as the main mechanisms associated with poorer recovery. Nagaoka et al. have reported that elevation of LDL/HDL cholesterol ration and/or hypertriglyceridemia were negatively associated with auditory gain [34], similarly Lin et al. [35] showed that comorbid diabetes or hypercholesterolemia were associated with poorer recovery. Our group has recently reported that total cholesterol concentrations were a negative prognostic factor for recovery in ISSHL. The endothelial dysfunction predisposing to the development of a prothrombotic state at the level of the inner ear that impairs cochlear membrane functions was proposed as the responsible mechanisms [36].

Conclusions

MetS was associated with ISSHL and this association negatively influenced the hearing recovery of these patients. Endothelial dysfunction and microvascular damage could be responsible to both the increased prevalence and poorer recovery of ISSHL.
Supporting information

S1 Database.
(XLSX)

Author Contributions

Conceptualization: Massimo Rinaldi, Giada Cavallaro, Nicola Quaranta.
Data curation: Massimo Rinaldi, Giada Cavallaro, Marica Cariello, Natasha Scialpi, Nicola Quaranta.
Formal analysis: Massimo Rinaldi, Giada Cavallaro, Marica Cariello, Natasha Scialpi, Nicola Quaranta.
Writing – original draft: Massimo Rinaldi, Giada Cavallaro.
Writing – review & editing: Nicola Quaranta.

References

1. Stachler RJ, Chandrasekhar SS, Archer SM, Rosenfeld RM, Schwartz SR, Bams DM, et al. Clinical practice guideline: sudden hearing loss. Otolaryngol Head Neck Surg. 2012; 146(3 Suppl):S1–S35. https://doi.org/10.1177/0194599812438449 PMID: 22893545
2. Byl FM Jr. Sudden hearing loss: eight years’ experience and suggested prognostic table. Laryngoscope. 1984 May; 94(5 Pt 1):647–61. PMID: 6325838
3. Merchant SN, Durand ML, Adams JC. Sudden deafness: is it viral?. Otolaryngol Head Neck Surg. 2008; 70(1):52–62. https://doi.org/10.1177/0194599808325206
4. Quaranta N, De Ceglie V, D’Elia A. Endothelial Dysfunction in Idiopathic Sudden Sensorineural Hearing Loss: A Review. Audiol Res. 2016 Jul 27; 6(1):151. https://doi.org/10.4081/audiore.2016.151 PMID: 27588164
5. Ciccone MM, Cortese F, Pinto M, Di Teo C, Fornarelli F, Gesualdo M, et al. Endothelial function and cardiovascular risk in patients with idiopathic sudden sensorineural hearing loss. Atherosclerosis. 2012 Dec; 225(2):511–6. https://doi.org/10.1016/j.atherosclerosis.2012.10.024 PMID: 23102449
6. Lin RJ, Krali R, Westerberg BD, Chadha NK, Chau JK. Systematic review and meta-analysis of the risk factors for sudden sensorineural hearing loss in adults. Laryngoscope. 2012 Mar; 122(3):624–35. https://doi.org/10.1002/lary.22480 PMID: 22252719
7. Lin HC, Chao PZ, Lee HC. Sudden sensorineural hearing loss increases the risk of stroke: a 5-year follow-up study. Stroke. 2008 Oct; 39(10):2744–8. https://doi.org/10.1161/STROKEAHA.108.519090 PMID: 18583554
8. Chang TP, Wang Z, Winnick AA, Chuang HY, Urrutia VC, Carey JP, et al. Sudden Hearing Loss with Vertigo Portends Greater Stroke Risk Than Sudden Hearing Loss or Vertigo Alone. J Stroke Cerebrovasc Dis. 2018 Feb; 27(2):472–478. https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.09.033 PMID: 2910540
9. Kassi E, Pervanidou P, Kaltasa G, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med. 2011 May 5; 9:48. https://doi.org/10.1186/1741-7015-9-48 PMID: 21542944
10. Samson SL, Garber AJ. Metabolic syndrome. Endocrinol Metab Clin North Am. 2014 Mar; 43(1):1–23. https://doi.org/10.1016/j.ecl.2013.09.009 PMID: 24582089
11. The IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation. 2005. [http://www.idf.org/idf-worldwide-definition-metabolic-syndrome]. The IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation. 2005. [http://www.idf.org/idf-worldwide-definition-metabolic-syndrome].
12. Chien CY, Tai SY, Wang LF, et al. Metabolic Syndrome Increases the Risk of Sudden Sensorineural Hearing Loss in Taiwan: A Case-Control Study. Otolaryngol Head Neck Surg. 2015; 153(1):105–111. https://doi.org/10.1177/0194599815575713 PMID: 25905640
13. Zhang Y, Jiang Q, Wu X, Xie S, Feng Y, Sun H. The Influence of Metabolic Syndrome on the Prognosis of Idiopathic Sudden Sensorineural Hearing Loss. Otol Neurotol. 2019; 40(8):994–997. https://doi.org/10.1097/MAO.0000000000002352 PMID: 31335801
14. Jung SY, Shim HS, Hah YM, Kim SH, Yeo SG. Association of Metabolic Syndrome With Sudden Sensorineural Hearing Loss. JAMA Otolaryngol Head Neck Surg. 2018 Apr 1; 144(4):308–314. https://doi.org/10.1001/jamaoto.2017.3144 PMID: 29450496

15. Zhou Y, Qiu S, Liu D. Impact of metabolic syndrome on recovery of idiopathic sudden sensorineural hearing loss. Am J Otolaryngol. 2019 Jul-Aug; 40(4):573–576. https://doi.org/10.1016/j.amjoto.2019.05.011 PMID: 31109803

16. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012 Jul; 33(13):1635–701. https://doi.org/10.1039/eurheartjhso092 PMID: 22565213

17. Siegel LG. The treatment of idiopathic sudden sensorineural hearing loss. Otolaryngol Clin North Am. 1975 Jun; 8(2):467–73. PMID: 1153209

18. WHO. World Health Organization. 2011. Waist Circumference and Waist–Hip Ratio. At: http://whqlibdoc.who.int/publications/2011/9789241501491_eng.pdf.

19. Lee CM, Huxley RR, Wildman RP, Woodward M. Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. J Clin Epidemiol. 2008 Jul; 61(7):646–53. https://doi.org/10.1016/j.jclinepi.2007.08.012 PMID: 18359190

20. Buie JJ, Watson LS, Smith CJ, Sims-Robinson C. Obesity-related cognitive impairment: The role of endothelial dysfunction. Neurobiol Dis. 2019 Dec; 132:104580. https://doi.org/10.1016/j.nbd.2019.104580 PMID: 31454547

21. Nakashima T, Naganawa S, Sone M, Tominaga M, Hayashi H, Yamamoto H, et al. Disorders of cochlear blood flow. Brain Res Brain Res Rev. 2003 Sep; 43(1):17–28. https://doi.org/10.1016/s0165-0173(03)00189-9 PMID: 14499459

22. Fasano T, Pertinhez TA, Tribi L, Lasagni D, Pilia A, Vecchia L, et al. Laboratory assessment of sudden sensorineural hearing loss: A case-control study. Laryngoscope. 2017 Oct; 127(10):2375–2381. https://doi.org/10.1002/lary.26514 PMID: 28224621

23. Teranishi M, Katayama N, Uchida Y, Tominaga M, Nakashima T. Thirty-year trends in sudden deafness from four nationwide epidemiological surveys in Japan. Acta Otolaryngol. 2007 Dec; 127(12):1259–65. https://doi.org/10.1080/00016480701242410 PMID: 17851966

24. Kim MB. Diabetes mellitus and the incidence of hearing loss: a cohort study. Int J Epidemiol. 2017 Apr 1; 46(2):727. https://doi.org/10.1093/ije/dyw342 PMID: 28100581

25. Wackym PA, Linthicum FH Jr. Diabetes mellitus and hearing loss: clinical and histopathologic relationships. Am J Otol. 1986 May; 7(3):176–82. PMID: 3717308

26. Jalali MM, Nasimidoust Azgomi M. Metabolic syndrome components and sudden sensorineural hearing loss: a case-control study. Eur Arch Otorhinolaryngol. 2020 Jan 24. https://doi.org/10.1007/s00405-020-05808-z PMID: 31980887

27. Agrawal Y, Platz EA, Niparko JK. Prevalence of hearing loss and differences by demographic characteristics among US adults: data from the National Health and Nutrition Examination Survey, 1999–2004. Arch Intern Med. 2008; 168(14):1522–1530. https://doi.org/10.1001/archinte.168.14.1522 PMID: 18663164

28. Gates GA, Cobb JL, D’Agostino RB, Wolf PA. The relation of hearing in the elderly to the presence of cardiovascular disease and cardiovascular risk factors. Arch Otolaryngol Head Neck Surg. 1993 Feb; 119(2):156–61. https://doi.org/10.1001/archotol.1993.01880140038006 PMID: 8427676

29. Shargorodsky J, Curhan SG, Eavey R, Curhan GC. A prospective study of cardiovascular risk factors and incident hearing loss in men. Laryngoscope. 2010 Sep; 120(9):1887–91. https://doi.org/10.1002/lary.21039 PMID: 20715090

30. Chang IJ, Kang CJ, Yueh CY, Fang KH, Yeh RM, Tsai YT. The relationship between serum lipids and sudden sensorineural hearing loss: a systematic review and meta-analysis. PLoS One. 2015; 10(4):e0121025. Published 2015 Apr 13. https://doi.org/10.1371/journal.pone.0121025 PMID: 25866869

31. Kaneva AM, Yanov YK, Bojko SG, Kudryavoykh OE, Potolitsyna NN, Bojko ER, et al. The atherogenic index (ATH index) as a potential predictive marker of idiopathic sudden sensorineural hearing loss: a case control study. Lipids Health Dis. 2019 Mar 15; 18(1):64. https://doi.org/10.1186/s12944-019-1016-5 PMID: 30876416

32. Lee JS, Kim DH, Lee HJ, Kim HJ, Koo JW, Choi HG, et al. Lipid profiles and obesity as potential risk factors of sudden sensorineural hearing loss. PLoS One. 2015 Apr 10; 10(4):e0122496. https://doi.org/10.1371/journal.pone.0122496 PMID: 25860024
33. Ryu OH, Choi MG, Park CH, Kim DK, Lee JS, Lee JH. Hyperglycemia as a potential prognostic factor of idiopathic sudden sensorineural hearing loss. Otolaryngol Head Neck Surg. 2014 May; 150(5):853–8. https://doi.org/10.1177/0194599814521012 PMID: 24482347

34. Nagaoka J, Anjos MF, Takata TT, Chaim RM, Barros F, Penido Nde O. Idiopathic sudden sensorineural hearing loss: evolution in the presence of hypertension, diabetes mellitus and dyslipidemias. Braz J Otorhinolaryngol. 2010 May-Jun; 76(3):363–9. PMID: 20658017

35. Lin CF, Lee KJ, Yu SS, Lin YS. Effect of comorbid diabetes and hypercholesterolemia on the prognosis of idiopathic sudden sensorineural hearing loss. Laryngoscope. 2016 Jan; 126(1):142–9. https://doi.org/10.1002/lary.25333 PMID: 25945947

36. Quaranta N, Squeo V, Sangineto M, Graziano G, Sabbà C. High Total Cholesterol in Peripheral Blood Correlates with Poorer Hearing Recovery in Idiopathic Sudden Sensorineural Hearing Loss. PLoS One. 2015 Jul 24; 10(7):e0133300. https://doi.org/10.1371/journal.pone.0133300 PMID: 26208311